Can ICON turn governance repair into renewed momentum for clinical research services?
ICON’s restatement and backlog reset test CRO confidence as pharma sponsors weigh execution risk, trial demand and 2026 recovery signals.
Why Thermo Fisher’s new Gothenburg lab matters for the next phase of complex drug development
Complex therapies need deeper trial data. Thermo Fisher’s Gothenburg lab shows why bioanalysis is becoming a CRO battleground.
Kexing Biopharm leans on IQVIA as biosimilar competition moves from China to global markets
Biosimilars need speed, but regulators still demand proof. IQVIA and Kexing test whether AI can cut friction without cutting evidence.
How AstraZeneca’s Owkin deal could push agentic AI deeper into drug development
Pharma has too much data and too little time. AstraZeneca’s Owkin deal tests whether agentic AI can sharpen drug development decisions.
Paradigm Health’s FDA collaboration puts clinical trial data automation under the spotlight
FDA review is moving closer to real time. Paradigm Health’s pilot with Amgen and AstraZeneca could reset clinical trial infrastructure.
Why Psyence Biomedical Ltd.’s Australian trial strategy could shape global psychedelic drug development pathways
Psyence Biomedical Ltd. advances NPX-5 dosing in Australia. Discover how this trial strategy could shape global psychedelic drug development.
Why the Terns acquisition matters more for Merck’s long-term pipeline strategy than its near-term revenue
Merck has begun its tender offer for Terns Pharmaceuticals. Read what the deal could change for metabolic drug competition and pipeline strategy.
Can Lunai Bioworks Inc.’s BBB delivery platform unlock scalable Alzheimer’s drug development advantages?
Can Lunai Bioworks Inc. overcome the blood brain barrier in Alzheimer’s treatment? Discover what this $20M deal changes for CNS drug development.
Curi Bio and Battelle commercialise human NMJ assay as GLP-ready alternative to mouse bioassay for botulinum toxin testing
Curi Bio and Battelle partner to commercialise a human NMJ assay for botulinum toxin potency testing. What this changes for NAM adoption and the mouse bioassay. Read more.
Ventyx to give Lilly an oral inflammation pipeline—what’s the real upside?
Eli Lilly and Company has announced plans to acquire Ventyx Biosciences Inc. in an all-cash transaction valued at approximately $1.2 billion, securing a portfolio of clinical-stage oral small molecule therapeutics focused on chronic inflammatory-mediated diseases. The deal includes NLRP3 inhibitors such as VTX2735 and VTX3232, alongside two Phase 2 programs for inflammatory bowel disease. The […]